Attralus Announces Publication of Two Studies Evaluating Iodine (124I) Evuzamitide (AT-01) using PET/CT in the Journal of American College of Cardiology (JACC CV Imaging)
Retrieved on:
Tuesday, November 7, 2023
MCF, Quality of life (healthcare), HIV disease progression rates, CMP, ID, Amyloid cardiomyopathy, Echocardiography, MRI, MPH, Health, Troponin, Cardiology, Cardiac amyloidosis, GLS, Journal, BWH, University, Patient, N-terminal prohormone of brain natriuretic peptide, Amyloidosis, Heart, LV, Publication, JACC, PET, Quality of life, TBR, Editorial, PET/CT, CAA, Amyloid, Harvard Medical School, ATTR, Devouring Radiant Light, Literature, Alys, Diagnosis, ECV, SAN, Medical imaging, Hospital, AL amyloidosis, Medicine, Iodine, Brigham
124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.
Key Points:
- 124I-evuzamitide may be more sensitive than standard diagnostics, with cardiac uptake shown in ATTR patients who had negative 99mTc-PYP scans.
- The manuscripts from Brigham and Women’s Hospital (BWH) and from the University of Tennessee Graduate School of Medicine were published in the Journal of American College of Cardiology – Cardiovascular Imaging (JACC CV Imaging).
- The manuscripts, entitled “Cardiac Amyloid Quantification Using 124I-Evuzamitide (124I-P5+14) Versus 18F-Florbetapir” and “Cardiac Amyloid Detection by PET/CT Imaging of Iodine (124I) Evuzamitide (124I-p5+14): A Phase 1/2 Study,” have been published online.
- These studies suggest that 124I-evuzamitide is a promising novel radiotracer to detect and quantify cardiac amyloid in multiple types of amyloidosis.